Terms: = Gastric cancer AND CD274, PDL1, 29126, ENSG00000120217, PDCD1L1, PD-L1, MGC142296, PDCD1LG1, MGC142294, B7H1, Q9NZQ7, B7-H AND Treatment
468 results:
1. The optimal threshold of pd-l1 combined positive score to predict the benefit of PD-1 antibody plus chemotherapy for patients with HER2-negative gastric adenocarcinoma: a meta-analysis.
Li JB; Lai MY; Lin ZC; Guan WL; Sun YT; Yang J; Wang WX; Yang ZR; Qiu MZ
Cancer Immunol Immunother; 2024 May; 73(7):132. PubMed ID: 38753055
[TBL] [Abstract] [Full Text] [Related]
2. [A Case of Advanced gastric cancer Treated with Conversion Surgery followed by Nivolumab Combination Chemotherapy].
Sekino N; Natsume T; Tanaka H; Kainuma O; Sato Y; Note H; Yoshioka T; Kamata T; Odera H; Uchiyama M; Maruyama T; Takahashi H; Hirano S
Gan To Kagaku Ryoho; 2024 Apr; 51(4):417-420. PubMed ID: 38644309
[TBL] [Abstract] [Full Text] [Related]
3. [Enhancing survival outcomes in stage Ⅲ gastric/esophagogastric junction cancer: a retrospective study of immune checkpoint inhibitors and adjuvant chemotherapy based on real-world data].
Yang XQ; Rao Z; Wei HK; Xue ZC; Liu HY; Duan QF; Sun XW; Wang W
Zhonghua Wei Chang Wai Ke Za Zhi; 2024 Apr; 27(4):395-402. PubMed ID: 38644245
[No Abstract] [Full Text] [Related]
4. Identification of TAP1 as a T-cell related therapeutic target in gastric cancer by mediating oxalipliatin-related synergistic enhancement of immunotherapy.
Zhao Y; Liu Z; Deng K; Qu H; Zhang Q; Zhou P; Yang M; Yang X; Wang H; Li R; Xia J
Int Immunopharmacol; 2024 May; 132():111998. PubMed ID: 38593510
[TBL] [Abstract] [Full Text] [Related]
5. [Surgical management of gastric cancer in the era of immunotherapy].
Li ZY; Jia YN; Lu XX; Guan GM; Wang Q
Zhonghua Wai Ke Za Zhi; 2024 May; 62(5):353-358. PubMed ID: 38548601
[TBL] [Abstract] [Full Text] [Related]
6. Phase II trial of domatinostat (4SC-202) in combination with avelumab in patients with previously treated advanced mismatch repair proficient oesophagogastric and colorectal adenocarcinoma: EMERGE.
Cartwright E; Slater S; Saffery C; Tran A; Turkes F; Smith G; Aresu M; Kohoutova D; Terlizzo M; Zhitkov O; Rana I; Johnston EW; Sanna I; Smyth E; Mansoor W; Fribbens C; Rao S; Chau I; Starling N; Cunningham D
ESMO Open; 2024 Apr; 9(4):102971. PubMed ID: 38518549
[TBL] [Abstract] [Full Text] [Related]
7.
Cytryn SL; Pandit-Taskar N; Lumish MA; Maron SB; Gu P; Ku GY; Chou JF; Capanu M; Antoine A; Loegel D; Feder L; Philemond S; Lyashchenko SK; Lewis JS; Paroder V; Srivastava A; Tang LH; Schoder H; Janjigian YY
J Nucl Med; 2024 May; 65(5):722-727. PubMed ID: 38514081
[TBL] [Abstract] [Full Text] [Related]
8. Body composition change indices combined with Prognostic Nutritional Index predicts the clinical outcomes of patients with gastric cancer treated with immune checkpoint inhibitor.
Deng G; Zhu D; Du Z; Xue Y; Song H; Li Y
Cancer Med; 2024 Mar; 13(6):e7110. PubMed ID: 38506237
[TBL] [Abstract] [Full Text] [Related]
9. Gastroesophageal Adenocarcinomas With Defective Mismatch Repair: Current Knowledge and Clinical Management.
Strickland MR; Lander EM; Gibson MK; Ilson DH; Ajani JA; Klempner SJ
J Natl Compr Canc Netw; 2024 Mar; 22(3):. PubMed ID: 38503041
[TBL] [Abstract] [Full Text] [Related]
10. Association of lymphocyte subsets with the efficacy and prognosis of PD‑1 inhibitor therapy in advanced gastric cancer: results from a monocentric retrospective study.
Wang X; Liu X; Dai H; Jia J
BMC Gastroenterol; 2024 Mar; 24(1):113. PubMed ID: 38491354
[TBL] [Abstract] [Full Text] [Related]
11. Perioperative or neoadjuvant chemotherapy for locally advanced gastric or gastroesophageal junction cancer: from independent evidence in the West, the East, and Japan to global collaboration.
Nakayama I; Ohashi M; Nunobe S
Chin Clin Oncol; 2024 Feb; 13(1):8. PubMed ID: 38453658
[TBL] [Abstract] [Full Text] [Related]
12. How to use anti-PD-1 therapy in gastric cancer: the approach in the United States.
Ilson DH
Chin Clin Oncol; 2024 Feb; 13(1):7. PubMed ID: 38453657
[TBL] [Abstract] [Full Text] [Related]
13. Efficacy of ramucirumab combination chemotherapy as second-line treatment in patients with advanced adenocarcinoma of the stomach or gastroesophageal junction after exposure to checkpoint inhibitors and chemotherapy as first-line therapy.
Masetti M; Al-Batran SE; Goetze TO; Thuss-Patience P; Knorrenschild JR; Goekkurt E; Folprecht G; Ettrich TJ; Lindig U; Luley KB; Pink D; Dechow T; Sookthai D; Junge S; Loose M; Pauligk C; Lorenzen S
Int J Cancer; 2024 Jun; 154(12):2142-2150. PubMed ID: 38447003
[TBL] [Abstract] [Full Text] [Related]
14. Prognostic implications of tumor-infiltrating lymphocytes within the tumor microenvironment in gastric cancer.
Pereira MA; Ramos MFKP; Cardili L; de Moraes RDR; Dias AR; Szor DJ; Zilberstein B; Alves VAF; de Mello ES; Ribeiro U
J Gastrointest Surg; 2024 Feb; 28(2):151-157. PubMed ID: 38445936
[TBL] [Abstract] [Full Text] [Related]
15. Correlation of CT parameters and pd-l1 expression status in gastric cancer.
Xu M; Ren T; Deng J; Yang J; Lu T; Xi H; Yuan L; Zhang W; Zhou J
Abdom Radiol (NY); 2024 Apr; 49(4):1320-1329. PubMed ID: 38436699
[TBL] [Abstract] [Full Text] [Related]
16. Case report: A case of rare metastasis of gastric cancer to the axillary lymph node metastasis treated with combination immunotherapy.
Wang J; Cheng Y; Wang Y; Liu H; Wu S; Tian G; Qu J; Qu X
Front Immunol; 2024; 15():1331506. PubMed ID: 38404578
[TBL] [Abstract] [Full Text] [Related]
17. Real-world outcomes of third-line immune checkpoint inhibitors versus irinotecan-based chemotherapy in patients with advanced gastric cancer: a Korean, multicenter study (KCSG ST22-06).
Lim SH; Lee KW; Kim JJ; Im HS; Kim IH; Han HS; Koo DH; Cho JH; Maeng CH; Lee MY; Lee HJ; Kim JH; Park SG; Jung JY; Shin SH; Kim KH; Kim H; Oh SY; Kang M; Jung M; Rha SY
BMC Cancer; 2024 Feb; 24(1):252. PubMed ID: 38395832
[TBL] [Abstract] [Full Text] [Related]
18. Who Should Receive Immunotherapy for Advanced Gastroesophageal cancer?
Khateeb S; Cavalcante L; Alnairat N; Singh M; Sahin IH; Saeed A; Saeed A
Curr Treat Options Oncol; 2024 Apr; 25(4):496-509. PubMed ID: 38372852
[TBL] [Abstract] [Full Text] [Related]
19. Identification of the exosomal pd-l1 inhibitor to promote the PD-1 targeting therapy of gastric cancer.
Sun JG; Gao Y; Gao YS; Dai XJ; Chen P
Eur J Med Chem; 2024 Mar; 268():116182. PubMed ID: 38367489
[TBL] [Abstract] [Full Text] [Related]
20. treatment and prognostic implications of strong pd-l1 expression in primary hepatic sarcomatoid carcinoma.
Radhakrishnan S; Martin CA; Vij M; Subbiah K; Raju LP; Gowrishankar G; Veldore VH; Kaliamoorthy I; Rammohan A; Rela M
Immunotherapy; 2024 Apr; 16(6):371-379. PubMed ID: 38362631
[TBL] [Abstract] [Full Text] [Related]
[Next]
